Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
1997·5.860 Zitationen·Journal of Clinical Oncology
Volltext beim Verlag öffnen5.860
Zitationen
14
Autoren
1997
Jahr
Abstract
This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.
Ähnliche Arbeiten
The Clavien-Dindo Classification of Surgical Complications
2009 · 10.954 Zit.
Radiomics: Images Are More than Pictures, They Are Data
2015 · 7.988 Zit.
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 · 7.606 Zit.
TGF-β SIGNAL TRANSDUCTION
1998 · 7.559 Zit.
Pancreatic Cancer
2000 · 7.244 Zit.
Autoren
Institutionen
Themen
Pancreatic and Hepatic Oncology ResearchCancer Treatment and PharmacologyPharmacological Effects and Toxicity Studies